A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease

Movement Disorders

Volumn 13, Issue SUPPL. 1, 1998, Pages 49-54

  Lapchak, Paul A ^a  

^a NONE   (United States)

Author keywords

Neurotrophic; Phenotypic expression; Plasticity; Regeneration; Sinemet; Transforming growth factor; Tyrosine hydroxylase

Indexed keywords

CARBIDOPA PLUS LEVODOPA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR;

ANIMAL EXPERIMENT; BEHAVIOR; CONFERENCE PAPER; DRUG EFFECT; HUMAN; IMMUNOCYTOCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RHESUS MONKEY;

ANIMALS; ANTIPARKINSON AGENTS; CARBIDOPA; CORPUS STRIATUM; DOPAMINE; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; LEVODOPA; NERVE GROWTH FACTORS; NERVE REGENERATION; NERVE TISSUE PROTEINS; NEUROGLIA; NEURONAL PLASTICITY; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0031921658     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Lin L-F, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132.
2. Lapchak PA. Therapeutic potentials for GDNF based upon pharmacological activities in the CNS. Rev Neurosci 1996;7:165-176.
3. Lapchak PA, Miller PJ, Jiao S, Collins F, Araujo DM, Collins F. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 1996;5:197-205.
4. Lapchak PA, Gash DM, Collins F, Hilt D, Miller PJ, Araujo DM. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Exp Neurol 1997;145:309-321.
5. Araujo DM, Hilt DC, Miller PJ, Wen D, Jiao S, Lapchak PA. RET receptor tyrosine kinase immunoreactivity is altered in GDNF-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways. Neuroscience 1997;80:9-16.
6. Lapchak PA, Miller PJ, Collins F, Jiao S. GDNF attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997;78:61-72.
7. Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res 1997;747:92-102.
8. 125I]glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification. Neurosci Lett 1996;220:187-190.
9. Lapchak PA, Gash DM, Jiao S, Miller PJ, Hilt D. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Exp Neurol 1997;144: 29-34.
10. Lapchak PA, Jiao S, Miller PJ, et al. Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tissue Res 1996;286:179-189.
11. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and in patients with Parkinson's disease. Arch Neurol 1993;47:1290-1298.
12. 3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988;156:331-340.
13. 125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Submitted for publication.
14. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394.
15. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in GDNF-treated parkinsonian monkeys. Nature 1996;380:252-255.
16. Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular GDNF administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997;282:1396-1401.
17. Lapchak PA, Jiao S, Miller P. Temporal relationship between glial cell line-derived neurotrophic factor increased hypothalamic galanin content and decreased body weight. Neuroscience 1998. In press.
18. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease. Lancet 1976;1:292-296.
19. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease-clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworths Scientific, 1982:96-122.
20. Miyoshi Y, Zhang Z, Ovadia A, et al. GDNF-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 1997;42:208-214.
21. Hornynkiewicz O, Fish J. Biochemical pathophysiology in Parkinson's disease. Adv Neurol 1986;45:19-34.
22. Adams RD, Victor M. Degenerative diseases of the nervous system. In: Adams RD, ed. Principles of neurology. New York, NY: McGraw Hill, 1993.